BPTH Stock Overview
Operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Bio-Path Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.15 |
| 52 Week High | US$4.55 |
| 52 Week Low | US$0.12 |
| Beta | 0.023 |
| 1 Month Change | -16.26% |
| 3 Month Change | -80.28% |
| 1 Year Change | -94.26% |
| 3 Year Change | -99.77% |
| 5 Year Change | -99.85% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate
Nov 05
Bio-Path GAAP EPS of -$0.42 beats by $0.07
Aug 16Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?
Jul 08Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation
Mar 24Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans
Aug 17We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully
Mar 26Shareholder Returns
| BPTH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.4% | 2.8% | 3.0% |
| 1Y | -94.3% | -6.8% | 10.1% |
Return vs Industry: BPTH underperformed the US Biotechs industry which returned -6.8% over the past year.
Return vs Market: BPTH underperformed the US Market which returned 10.1% over the past year.
Price Volatility
| BPTH volatility | |
|---|---|
| BPTH Average Weekly Movement | 31.3% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: BPTH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BPTH's weekly volatility (31%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 10 | Peter Nielsen | www.biopathholdings.com |
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company’s lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML).
Bio-Path Holdings, Inc. Fundamentals Summary
| BPTH fundamental statistics | |
|---|---|
| Market cap | US$1.25m |
| Earnings (TTM) | -US$9.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs BPTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BPTH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$9.89m |
| Earnings | -US$9.89m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.19 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BPTH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/04 22:33 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bio-Path Holdings, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | Maxim Group |
| Pamela Bassett | Maxim Group |
| Raghuram Selvaraju | Rodman & Renshaw, LLC |